Lab Groups Disagree With GAO That Medicare Will Be Overbilled For PAMA Test Payments
A coalition of US laboratories and diagnostic test-makers say it strongly disagrees with GAO’s conclusions that labs will be overbilling Medicare for future payments under the “Protecting Access To Medicare Act of 2014”, and sent a letter to GAO managers last week arguing its case.
You may also be interested in...
A crop of new US consumer protection state laws and proposed federal legislation is aimed at stopping medical specialists from the practice of balance billing.
Senate Finance Committee Chairman Chuck Grassley says Medicare would be overpaying for laboratory tests if it goes forward with its planned increases to diagnostic prices on the Medicare Clinical Lab Fee Schedule (CLFS). Industry groups disagree.
The US FDA wants to expand the availability of surgical apparel – including gowns, hoods and examination gloves – for health care professionals to use for the duration of the COVID-19 public health crisis. That means the agency will “not object” to the use of gowns and gloves providing low-to-minimal protection, as long as they do not create an undue risk to patients or users.